FZJ-003 / Shanghai Fudan-Zhangjiang - LARVOL DELTA

Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion

Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib. (PubMed, Eur J Pharm Sci) - "Unlike filgotinib, there was no obvious amide-hydrolyzed metabolite of FZJ-003 detected throughout the pre-systemic metabolic sites. Collectively, these data suggest that the higher systemic exposure of FZJ-003 than filgotinib is mainly attributed to the higher intestinal bioavailability including bypassing the amide hydrolysis and possible efflux by intestinal epithelial cells, which strongly support the structural design purpose in terms of pharmacokinetics."

Journal • Anesthesia • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • JAK1